S
Last Price
52 Week Range
€0.58 - €3.89
Next Earnings Date
Apr 08 2026 (Estimate)
Next Earnings Date
Apr 08 2026 (Est.)
Last Price
Market Cap | €38.30M |
EV | €72.38M |
Shares Outstanding | 60.40M |
Beta | -0.64 |
Industry | Medical - Devices |
Analyst Rating | OUTPERFORM |
Analyst Target Price | |
Number of Analysts | 3 |
P/E 2025E | - |
P/Revenue 2025E | 54.71x |
Revenue | |
EPS | |
Operating Cash Flow | |
Free Cash Flow |
Revenue | |
EPS | |
Operating Cash Flow | |
Free Cash Flow |
Gross Margin 2025E | 80.00% |
Net Profit Margin 2025E | -1925.71% |
ROE 2025E | - |
ROCE 2024 | - |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR |
Price
%
1M
3M
6M
1Y
3Y
5Y
S
Sequana Medical NV
SEQUA
Sector
Healthcare
Industry
Medical - Devices
CEO
Crosbie, Ian
Employees
48
Website
www.sequanamedical.comIPO Date
2019-02-11
Headquarters
Kortrijksesteenweg 1112, box 102, Sint-Denijs-Westrem, Gent, East Flanders, 9051, Belgium
The last closing price of Sequana Medical NV (SEQUA) is €0.62, reflecting a +2.66% change from the prior session. Last updated: December 31, 2025 at 6:57 AM Eastern Time
Review the recent SEQUA stock performance trends:Past 1 Month: Sequana Medical NV (SEQUA) shares have -16.80%.Past 3 Months: The stock has -17.45%.Past 6 Months: SEQUA shares have -58.83%. Last updated: December 31, 2025 at 11:44 PM Eastern Time
Over the last year, Sequana Medical NV (SEQUA) has established a 52-week price range between a high of €3.89 and a low of €0.58. This metric is essential for assessing the stock's annual volatility. Last updated: December 31, 2025 at 11:44 PM Eastern Time
Sequana Medical NV (SEQUA) is considered a low volatility stock. It has a beta of -0.64, which means it typically moves in the opposite direction of the broader market, with a magnitude of approximately 0.64 times the market's movement. Over the past 52 weeks, SEQUA has traded within a €0.58 – €3.89 range. Last updated: December 31, 2025 at 11:44 PM Eastern Time
Based on current SEQUA analyst forecasts and market assumptions, the consensus price target for Sequana Medical NV (SEQUA) is €2.73 for 2027. Relative to the current price of €0.62, this implies a positive upside of +331.13%. Price targets reflect forward-looking estimates based on information available at the time and are inherently subject to change as underlying assumptions, company fundamentals, or market conditions evolve. Last updated: December 31, 2025 at 11:44 PM Eastern Time
A €1,000 investment in Sequana Medical NV 5 years ago, when the stock was trading around €11.54, would be worth approximately €53.71 today, based solely on share price performance (excluding dividends). This represents a total return of -94.63% over the period, equivalent to a compound annual growth rate (CAGR) of -44.28%. Past performance reflects historical price movements only and does not imply future results. Last updated: December 31, 2025 at 11:44 PM Eastern Time
The current Sequana Medical NV (SEQUA) market capitalization is approximately €38.30M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Sequana Medical NV's market cap fluctuates with changes in its share price and share count. Last updated: December 31, 2025 at 11:44 PM Eastern Time
In the most recently reported quarter, Sequana Medical NV (SEQUA) generated €0.00 in revenue, representing a -100.00% year over year change. For the next quarter, analyst consensus currently expects revenue of approximately €0.00, implying an expected -100.00% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: January 1, 2026 at 2:27 AM Eastern Time
In the most recently reported fiscal year, Sequana Medical NV (SEQUA) generated net income of €-44.65M, compared with €-32.56M in the prior fiscal year, representing a -37.13% year over year change. For the upcoming fiscal year, analyst consensus currently estimates net income of €-13.48M. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: January 1, 2026 at 2:27 AM Eastern Time
According to its latest quarterly filing, Sequana Medical NV (SEQUA) reported EBITDA of €-4.48M, representing a +35.43% year over year change. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: January 1, 2026 at 2:27 AM Eastern Time
Based on the latest available data, Sequana Medical NV (SEQUA) is currently trading at a last twelve months (LTM) P/E ratio of -0.53x. Looking forward, the stock trades at a next twelve months (NTM) P/E ratio of -1.99x, based on consensus earnings estimates. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: January 1, 2026 at 2:27 AM Eastern Time
Sequana Medical NV (SEQUA) is currently scheduled to report its next earnings results on April 7, 2026. Earnings dates are subject to change and may be updated by the company with limited notice. Investors typically monitor upcoming earnings releases closely, as they can result in increased volatility depending on reported results, forward guidance, and management commentary. Last updated: December 31, 2025 at 11:44 PM Eastern Time
In the most recently reported quarter, Sequana Medical NV (SEQUA) revenue was €0.00, compared with analyst consensus expectations of €100.00K, representing a -100.00% revenue surprise versus expectations. Earnings per share (EPS) for the quarter were €-0.41, compared with consensus estimates of €-0.12, resulting in an -239.98% EPS surprise. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: January 1, 2026 at 2:27 AM Eastern Time
Sequana Medical NV (SEQUA) does not currently pay a dividend. Over the last twelve months (LTM), the company paid €0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: January 1, 2026 at 2:27 AM Eastern Time
Analyst assessments of whether Sequana Medical NV (SEQUA) consensus price target is overvalued or undervalued are generally expressed relative to consensus valuation frameworks and price targets, rather than as an absolute judgment.Current share price: €0.62Consensus price target: €2.73Implied return: +331.13% An implied return above current levels indicates that, on average, analysts view the stock as trading below their estimated fair value. Conversely, an implied return below current levels suggests the stock may be fully valued or priced above consensus expectations. This content is for informational purposes only and does not constitute investment advice. Last updated: January 1, 2026 at 2:27 AM Eastern Time
Based on the latest available analyst coverage, Sequana Medical NV (SEQUA) currently carries a Outperform consensus rating. Analysts' average SEQUA price target is €2.73. Relative to the current share price of €0.62, this suggests a potential price change of approximately +331.13%. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: January 1, 2026 at 2:27 AM Eastern Time
Like other publicly traded stocks, Sequana Medical NV (SEQUA) shares are bought and sold on stock exchanges such as ENXTBR and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Sequana Medical NV (SEQUA) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.
At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add SEQUA to your watchlist.
Sequana Medical NV trades under the ticker symbol SEQUA on the ENXTBR stock exchange. The ticker SEQUA is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.
As of the most recently reported period, Sequana Medical NV (SEQUA) employs approximately 48 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: December 31, 2025 at 11:44 PM Eastern Time
Sequana Medical NV (SEQUA) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Sequana Medical NV (SEQUA) stock peers based on overlapping products, services, and competitive dynamics:Ambu (AMBU B)LivaNova (LIVN)AtriCure (ATRC)CVRx (CVRX)Nuwellis (NUWE)enVVeno Medical (NVNO)MicroPort NeuroScientific (2172)Sino Medical Sciences Technology (688108) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Sequana Medical NV.
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.